Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration

Victoria Mary McLeod, Linda Jiaying Chan, Gemma Ryan, Christopher John Porter, Lisa Michelle Kaminskas

Research output: Contribution to journalArticleResearchpeer-review

25 Citations (Scopus)

Abstract

The utility of inhaled protein therapeutics to treat lung-resident diseases is limited by protein degradation in the lungs and rapid clearance. This study therefore aimed to evaluate the impact of PEGylation on the lung and systemic exposure of interferon (IFN) α2 after intratracheal administration to rats. An inverse correlation was observed between PEG chain length and systemic exposure, where bioavailability was 5.5% for the 31 kDa PEGylated construct and <0.4% for the 60 kDa PEGylated construct when compared with 15% for native IFN (19 kDa). Retention of PEGylated IFNα within the lungs increased 2.5-fold to threefold when compared with native IFN. When comparing the lung and systemic exposure of PEGylated and native IFN in terms of protein biological activity, the 31 kDa PEGylated construct increased exposure by 50% and 100%, respectively, when compared with native IFN, but the 60 kDa PEG construct offered no benefit. Preliminary work also indicated that the conjugation of IFNγ with 10 kDa PEG significantly increases the retention of the protein within the lung. Optimal PEGylation may therefore be used as a means to improve the exposure of lung-resident diseases to therapeutic cytokines and potentially reduce systemic exposure and side effects as well as dosing frequency.
Original languageEnglish
Pages (from-to)1421-1430
Number of pages10
JournalJournal of Pharmaceutical Sciences
Volume104
Issue number4
DOIs
Publication statusPublished - 2015

Keywords

  • bioavailability
  • interferon
  • lung retention
  • pegylation
  • pharmacokinetics
  • protein delivery
  • pulmonary drug delivery

Cite this